All Articles

The day after Thanksgiving is a plumber's Super Bowl. Discover why 'Brown Friday' causes a surge in emergency calls, how to prevent drain disasters, and how one Oklahoma company is giving back to the community.

Dallas-based financial tech firm, MUFG Capital Analytics, is recognized for its strong culture and employee engagement, aligning with parent company’s global growth strategy.

Ocean robotics firm Nauticus Robotics reports Q3 2025 earnings, showcasing revenue gains but continued net losses. Analysts weigh the company's path to profitability in a booming subsea services sector.

EBC Financial Group partners with the University of Oxford to address accessibility gaps in financial education. Can this collaboration truly 'democratize' finance, or is it a branding exercise?

Danone Canada is making a significant investment in its Boucherville, Quebec plant, expanding production capacity while doubling down on sustainable practices and solidifying its commitment to the Canadian market.

New research shows the range-extended EV market is booming, forecast to reach 3.2 billion units by 2030, with China leading innovation & sales. Is this the bridge to full EV adoption?

A new market intelligence report dives deep into the hyperglycemia clinical trial landscape, offering insights into investment trends, key players, and the potential for more efficient drug development. Will better data translate to faster breakthroughs?

New analysis exposes gaps in how countries address food systems’ impact on climate change, highlighting the need for urgent reform and demand-side solutions.

Demand for recycled plastics is booming, fueled by sustainability initiatives and technological advancements. But supply chain issues, quality control, and regulatory hurdles remain key obstacles to wider adoption.

A new report analyzing clinical trials for ANCA Vasculitis reveals a growing pipeline of potential therapies and burgeoning investment in the rare autoimmune disease, signaling a shift toward precision medicine.

A new report details the burgeoning STAT inhibitor pipeline, highlighting promising new therapies for cancer and inflammatory diseases, but recent trial data reveals challenges and strategic shifts for key players.

A new report analyzes global bronchitis clinical trials, revealing key investment opportunities and strategies for improving trial efficiency. Experts highlight the rise of novel therapies and personalized treatment approaches.

New market research highlights a surge in sleep apnea clinical trials, driven by demand for improved treatments beyond CPAP. Explore the pipeline, investment landscape, and impact on a $8.66B market.

A new report highlights a robust psoriasis treatment pipeline, with late-stage trials and approvals driving growth. Market analysis points to significant investment potential in innovative therapies and biosimilar development.

A new report sheds light on the growing Amyloidosis therapeutics market, detailing clinical trial activity, cost-effectiveness, and investment opportunities in this critical rare disease space.

New analysis of global dengue fever clinical trials points to a surge in R&D, with Takeda & Sanofi leading the charge, and emerging players in India & China gaining traction. The report provides critical insights for investors and public health officials.

A new analysis sheds light on the evolving clinical trial landscape for rhabdomyosarcoma, a rare childhood cancer, revealing increasing investment and promising therapeutic approaches. The report highlights key players and growth drivers.

A surge of investment and promising new therapies are transforming the spasticity treatment landscape, with a projected $9.6 billion market opportunity by 2030. Explore the key players and pipeline drugs poised to reshape care for millions.

A new report analyzes the burgeoning Gaucher disease clinical trial landscape, revealing growth opportunities for investors and hope for patients with this rare genetic disorder. Gene therapy and novel treatments are driving innovation.

A surge in R&D is reshaping the diabetic retinopathy treatment landscape, with a robust pipeline of novel therapies poised to address limitations of current anti-VEGF treatments and improve patient outcomes.